Which statin side effects are supported by blinded trials?

Blinded-trial evidence supported increased liver-test abnormalities but did not show excess risk for most other outcomes attributed to statins in product labels. Previously established muscle and diabetes risks remain clinically relevant.

This episode discusses a meta-analysis, not a single randomised trial.

Reference: Cholesterol Treatment Trialists’ (CTT) Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. Lancet. 2026;407(10529):689–703. doi:10.1016/S0140-6736(25)01578-8. PMID:41655587.

Chapters

0:00 Introduction

0:38 The evidence

3:11 Interpretation

3:48 Outro

Read the structured summary at https://hormoneinsight.com

AI narration is used. This podcast is intended for healthcare professionals and is educational, not medical advice. Views are the presenter’s own and do not necessarily reflect those of any institution with which he works.

Hormone Insight: https://hormoneinsight.com

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en